2018 International Congress

Saturday, October 6, 2018

1:45pm-3:15pm

Dopaminergics are alternative for the treatment of Bell`s paralysis in acute period

A. Azimov, R. Sadykov, G. Rakhimbaeva, F. Azimov (Tashkent, Uzbekistan)

Neuropharmacology  ·  Hall 3FG

1:45pm-3:15pm

Double-blind controlled trial of Spectramax™ light therapy for the treatment of Parkinson’s disease patients on stable dopaminergic therapy

A. Videnovic, S. Rutten, W. Croft, H. Erickson, J. Groves, C. Havemann, T. Herrington, S. Hendrix, K. Kieburtz, Y. vander Werf, O. vanden Heuvel (Boston, MA, USA)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Dual Competition between the Basal Ganglia and the Cortex: 1 from Action-Outcome to Stimulus-Response

T. Boraud (Bordeaux, France)

Neurophysiology (Non-PD)  ·  Hall 3FG

1:45pm-3:15pm

Dual device aided therapy for patients with advanced Parkinson’s Disease: A case series

A. Faust- Socher, G. Yahalom, M. Kestenbaum, A. Hilel, S. Israeli-Korn, A. Thaler, H. Strauss, H. Shabtai, S. Hassin-Baer, N. Giladi, T. Gurevich, O. Cohen (Tel Aviv, Israel)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Dual task in the daily life of patients with Parkinson’s disease

K. Mejia (Lima, Peru)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Dyskinesia management in COMT-naïve patients starting adjunctive therapy with opicapone: The BIPARK-I double-blind experience

J. Pagonabarraga, E. Tolosa, J. Ferreira, A. Lees, E. Arbe, J. Rocha, P. Soares-da-Silva (Barcelona, Spain)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Dyskinesia-hyperpyrexia syndrome (DHS) after sudden interruption of deep brain stimulation and increase of oral dopaminergic therapy: A case report

F. Dematteis, A. Cormio, C. Fronda, M. Lanotte, M. Zibetti, S. Amarù, L. Lopiano, M. Rizzone (Rivoli, Italy)

Surgical Therapy: Parkinson's Disease  ·  Hall 3FG

1:45pm-3:15pm

Dysphagia predicts poor outcome in late-stage Parkinson’s disease

M. Fabbri, D. Abreu, L. Guedes, M. Rosa, A. Antonini, M. Zibetti, L. Lopiano, J. Fereira, M. Coelho (Lisbon, Portugal)

Parkinson’s Disease: Clinical Trials, Pharmacology And Treatment  ·  Hall 3FG

1:45pm-3:15pm

Dystonia ataxia (DYTCA) syndrome with prominent handwriting deterioration associated with ADCK3 mutation: two new cases and an overview of the literature

S. Galosi, T. Schirinzi, E. Bertini, R. Haas, F.M. Santorelli, V. Leuzzi, J.R. Friedman (Rome, Italy)

Rare Genetic and Metabolic Diseases  ·  Hall 3FG

1:45pm-3:15pm

Economics of Botulinum Toxin Therapy: Influence of the AbobotulinumtoxinA Package Size on the Costs of Botulinum Toxin Therapy

F. Adib Saberi, D. Dressler (Hamburg, Germany)

Neuropharmacology  ·  Hall 3FG